Keros Therapeutics Inc (KROS)
60.35
-2.72
(-4.31%)
USD |
NASDAQ |
Nov 14, 16:00
60.35
0.00 (0.00%)
After-Hours: 20:00
Keros Therapeutics Enterprise Value: 2.024B for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 2.024B |
| November 12, 2024 | 2.097B |
| November 11, 2024 | 2.230B |
| November 08, 2024 | 2.220B |
| November 07, 2024 | 2.190B |
| November 06, 2024 | 2.161B |
| November 05, 2024 | 2.004B |
| November 04, 2024 | 1.898B |
| November 01, 2024 | 1.897B |
| October 31, 2024 | 1.820B |
| October 30, 2024 | 1.811B |
| October 29, 2024 | 1.830B |
| October 28, 2024 | 1.853B |
| October 25, 2024 | 1.855B |
| October 24, 2024 | 1.808B |
| October 23, 2024 | 1.746B |
| October 22, 2024 | 1.799B |
| October 21, 2024 | 1.837B |
| October 18, 2024 | 1.874B |
| October 17, 2024 | 1.868B |
| October 16, 2024 | 1.910B |
| October 15, 2024 | 1.840B |
| October 14, 2024 | 1.844B |
| October 11, 2024 | 1.816B |
| October 10, 2024 | 1.738B |
| Date | Value |
|---|---|
| October 09, 2024 | 1.745B |
| October 08, 2024 | 1.812B |
| October 07, 2024 | 1.830B |
| October 04, 2024 | 1.860B |
| October 03, 2024 | 1.821B |
| October 02, 2024 | 1.876B |
| October 01, 2024 | 1.817B |
| September 30, 2024 | 1.749B |
| September 27, 2024 | 1.712B |
| September 26, 2024 | 1.728B |
| September 25, 2024 | 1.712B |
| September 24, 2024 | 1.680B |
| September 23, 2024 | 1.641B |
| September 20, 2024 | 1.688B |
| September 19, 2024 | 1.745B |
| September 18, 2024 | 1.684B |
| September 17, 2024 | 1.659B |
| September 16, 2024 | 1.681B |
| September 13, 2024 | 1.732B |
| September 12, 2024 | 1.710B |
| September 11, 2024 | 1.648B |
| September 10, 2024 | 1.646B |
| September 09, 2024 | 1.616B |
| September 06, 2024 | 1.564B |
| September 05, 2024 | 1.608B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
397.04M
Minimum
Jun 28 2022
2.230B
Maximum
Nov 11 2024
1.026B
Average
972.35M
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 798.35B |
| Regeneron Pharmaceuticals Inc | 80.57B |
| Scholar Rock Holding Corp | 2.051B |
| NovaBay Pharmaceuticals Inc | 2.762M |
| Palatin Technologies Inc | 13.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -52.96M |
| Revenue (Quarterly) | 0.388M |
| Total Expenses (Quarterly) | 59.04M |
| EPS Diluted (Quarterly) | -1.41 |
| Profit Margin (Quarterly) | -13.65K% |
| Earnings Yield | -8.63% |
| Normalized Earnings Yield | -9.611 |